Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 2.04 NOK
Change Today -0.04 / -1.92%
Volume 153.6K
BIONOR On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
OTC US
As of 10:25 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

bionor pharma asa (BIONOR) Snapshot

Open
2.08 NOK
Previous Close
2.08 NOK
Day High
2.17 NOK
Day Low
2.03 NOK
52 Week High
05/4/15 - 3.33 NOK
52 Week Low
03/18/15 - 2.02 NOK
Market Cap
507.9M
Average Volume 10 Days
256.5K
EPS TTM
-0.28 NOK
Shares Outstanding
249.0M
EX-Date
12/12/03
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIONOR PHARMA ASA (BIONOR)

Related News

No related news articles were found.

bionor pharma asa (BIONOR) Related Businessweek News

No Related Businessweek News Found

bionor pharma asa (BIONOR) Details

Bionor Pharma ASA, a biotechnology company, engages in developing peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). The company’s HIV vaccine candidates in clinical development include Vacc-4x for reducing viral load and killing virus producing cells; and Vacc-C5, a humoral (antibody-mediated) peptide-based therapeutic HIV-1 vaccine. The company is also developing Vacc-HIV, a preclinical phase vaccine, using the combination of Vacc-4x and Vacc-C5 vaccines; and Vacc-FLU, a preclinical phase influenza vaccine. In addition, it is developing vaccines for other viral diseases, including Hepatitis C, cytomegalovirus infection, and human papillomavirus infection. Further, the company provides nutraceutical products, such as Nutri5 and NutriPro. It operates in Norway and Europe, including Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is based in Oslo, Norway.

10 Employees
Last Reported Date: 04/13/15
Founded in 1993

bionor pharma asa (BIONOR) Top Compensated Officers

Head of Development and Executive Vice Presid...
Total Annual Compensation: 1.9M NOK
Compensation as of Fiscal Year 2013.

bionor pharma asa (BIONOR) Key Developments

Bionor Enters into Romidepsin Supply Agreement Enabling Advancement of its HIV Therapeutic Vaccine with Vacc-4x into Full Scale Clinical Phase II

Bionor Pharma ASA has signed an agreement with Celgene Corporation (Celgene) securing a continued supply of romidepsin (Istodax(Registered)) for use in a planned multicenter clinical Phase II study of Bionor's most advanced and proprietary vaccine, Vacc-4x, with romidepsin. The planned study will continue to explore the 'Kick and Kill' strategy of Bionor's ongoing REDUC study, for which Celgene also supplies romidepsin. In Part A of the REDUC study, completed in 2014, it was demonstrated that romidepsin was safe, well tolerated and able to release HIV viral DNA from latent reservoirs into the blood stream in HIV infected patients on anti-retroviral treatment. An interim analysis of Part B of the REDUC study announced on 4 May 2015 indicated killing of reactivated HIV and reduction in latent viral reservoir when patients received Vacc-4x prior to romidepsin.

Bionor Pharma ASA Announces Board Changes

Bionor Pharma ASA at its AGM held on May 13, 2015, approved the appointment of Russell G. Greig as Chairman of the Board of the directors for the period of two years. Thomas Hofstaetter, Bernd R. Seizinger and Kirsten Aarup Drejer was elected as new Board members for a period of two years. The Board members Jerry B. Zeldis and Benedicte Fossum were not up for election in 2015.

Bionor Pharma ASA Proposes to Approve Articles of Association

Bionor Pharma ASA announced that at its AGM held on May 13, 2015, the shareholders approved the amendments to its articles of association.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIONOR:NO 2.04 NOK -0.04

BIONOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIONOR.
View Industry Companies
 

Industry Analysis

BIONOR

Industry Average

Valuation BIONOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 747.4x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 628.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOR PHARMA ASA, please visit www.bionorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.